Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Other Accumulated Expenses (2021 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Other Accumulated Expenses for 5 consecutive years, with $54.7 million as the latest value for Q3 2025.

  • Quarterly Other Accumulated Expenses fell 62.88% to $54.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $54.7 million through Sep 2025, down 62.88% year-over-year, with the annual reading at $54.7 million for FY2025, 62.88% down from the prior year.
  • Other Accumulated Expenses hit $54.7 million in Q3 2025 for Universe Pharmaceuticals, down from $147.4 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $147.4 million in Q3 2024 to a low of $52263.0 in Q3 2022.
  • Historically, Other Accumulated Expenses has averaged $40.6 million across 5 years, with a median of $444319.0 in 2021.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 88.24% in 2022 and later soared 112404.1% in 2024.
  • Year by year, Other Accumulated Expenses stood at $444319.0 in 2021, then crashed by 88.24% to $52263.0 in 2022, then skyrocketed by 150.74% to $131045.0 in 2023, then skyrocketed by 112404.1% to $147.4 million in 2024, then tumbled by 62.88% to $54.7 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for UPC at $54.7 million in Q3 2025, $147.4 million in Q3 2024, and $131045.0 in Q3 2023.